Papers/PMID:27344135
Aripiprazole for autism spectrum disorders (ASD).
The Cochrane database of systematic reviews2016The record
1 finding · 1 compound · 1 endpoint
What it reported
How to read these marksWhat moved
1 finding
aripiprazole — increases body mass
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding“In terms of side effects, children/adolescents taking aripiprazole had a greater increase in weight, with a mean increase of 1.13 kg relative to placebo (95% CI 0.71 to 1.54, two studies, 308 children/adolescents, moderate-quality evidence), and had a higher risk ratio (RR) for sedation (RR 4.28, 95% CI 1.58 to 11.60, two studies, 313 children/adolescents, moderate-quality evidence) and tremor (RR 10.26, 95% CI 1.37 to 76.63, two studies, 313 children/adolescents, moderate-quality evidence).”
Quoted verbatim from Aripiprazole for autism spectrum disorders (ASD).. - Study
- meta-analysis
- Population
- Children and adolescents with autism spectrum disorder; two placebo-controlled RCTs of oral aripiprazole, eight weeks
Effect 1.13 mean difference, 95% CI 0.71 to 1.54
Aripiprazole for autism spectrum disorders (ASD).2016PMID:27344135Permalink